World Clinical Drugs, Volume. 46, Issue 7, 669(2025)
Efficacy of Sangbaipi decoction in treating acute exacerbation of chronic obstructive pulmonary disease with phlegm-heat stagnation in the lung syndrome and its impact on respiratory function
[3] [3] HAWKINS NM, NORDON C, RHODES K,et al. Heightened long-term cardiovascular risks after exacerbation of chronic obstructive pulmonary disease [J]. Heart, 2024, 110(10):702-709.
[10] [10] LONG B, REZAIE SR. Evaluation and management of asthma and chronic obstructive pulmonary disease exacerbation in the emergency department [J]. Emerg Med Clin North Am, 2022, 40(3): 539-563.
[13] [13] GRAUL EL, NORDON C, RHODES K,et al. Temporal risk of nonfatal cardiovascular events after chronic obstructive pulmonary disease exacerbation: a population-based study [J]. Am J Respir Crit Care Med, 2024, 209(8): 960-972.
[17] [17] SWART KMA, BAAK BN, LEMMENS L,et al. Risk of cardiovascular events after an exacerbation of chronic obstructive pulmonary disease: results from the EXACOS-CV cohort study using the PHARMO data network in the Netherlands [J]. Respir Res, 2023, 24(1): 293.
Get Citation
Copy Citation Text
ZHANG Haojie, ZHANG Hui, WANG Yayun. Efficacy of Sangbaipi decoction in treating acute exacerbation of chronic obstructive pulmonary disease with phlegm-heat stagnation in the lung syndrome and its impact on respiratory function[J]. World Clinical Drugs, 2025, 46(7): 669
Category:
Received: Mar. 2, 2025
Accepted: Aug. 26, 2025
Published Online: Aug. 26, 2025
The Author Email:
